<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/PT-2-18-11-2025-shutterstock_2309849697-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/PT-2-18-11-2025-shutterstock_2309849697-430x241.jpg"/></p>
<p>Halozyme 擁有專有酶 rHuPH20，支撐 Enhanze，這是一種快速皮下藥物遞送的解決方案。圖片來源：SaiArLawKa2/Shutterstock.com。</p>
<p>Merus 和 Halozyme 簽署了一項全球非獨佔合作和許可協議，用於 petosemtamab 的皮下製劑。</p>
<p>該協議涉及使用 Enhanze 藥物遞送技術開發和商業化 petosemtamab 的給藥，該藥物是一種表皮生長因子受體 (EGFR) 與富含亮氨酸重複的 G 蛋白偶聯受體 5 (LGR5) 的雙特異性抗體。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - Lemzoparlimab 在邊緣區 B 細胞淋巴瘤中的應用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - Lemzoparlimab 在腹膜癌中的應用</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>Merus 授權 Halozyme 的 Enhanze 技術，以加速皮下給藥的進展。</p>
<p>Halozyme 將獲得預付款、與商業里程碑和銷售成功相關的額外付款，以及在特許權使用費期間對使用該技術製備的 petosemtamab 的淨銷售額的低至中單數字的特許權使用費。</p>
<p>Merus 首席運營官兼總法律顧問 Peter Silverman 表示：“Petosemtamab 在眾多實體腫瘤癌症的臨牀研究中繼續顯示出令人鼓舞的結果，並有潛力成為頭頸癌及其他領域的首個和最佳治療方案。</p>
<p>“我們很自豪能與 Halozyme 合作，並期待與他們的團隊密切合作進行皮下給藥。”</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預測？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>由 GlobalData 提供</p>
<p>瞭解更多關於戰略情報</p>
<p>Halozyme 總裁兼首席執行官 Dr Helen Torley 表示：“我們很高興能與 Merus 合作，推進 r/m HNSCC 患者及其他潛在適應症的治療選擇。</p>
<p>“這次合作代表了我們 Enhanze 技術改善治療效率和提升患者治療體驗的新機會。我們共同的目標是加速患者和醫療提供者的創新。”</p>
<p>Halozyme 擁有酶 rHuPH20，支撐 Enhanze，這是一種快速皮下藥物遞送的解決方案，以減輕患者的治療負擔。</p>
<p>Enhanze 技術已被包括 Takeda、Roche、Janssen、Pfizer 和 AbbVie 在內的公司許可。</p>
<p>在 2025 年 9 月，Genmab 簽署了一項協議 以每股 97 美元的價格收購 Merus 的所有股份，此次全現金交易的估值為 80 億美元，增強了其腫瘤學管線。</p>
<h2>製藥技術卓越獎 - 參賽的好處</h2>
<p>獲得你應得的認可！製藥技術卓越獎 慶祝創新、領導力和影響力。通過參賽，你展示了你的成就，提升了你的行業形象，並將自己定位於推動製藥進步的頂尖領導者之中。不要錯過脱穎而出的機會——今天就提交你的參賽作品！</p>
<p>立即提名</p>

奧洛茲美醫療

MRUS

<p>Merus 和 Halozyme 已達成全球非獨佔合作和許可協議，涉及皮下給藥形式的 petosemtamab。這項合作包括使用 Halozyme 的 Enhanze 技術來增強 petosemtamab 的遞送，該藥物是一種 EGFR x LGR5 雙特異性抗體。Halozyme 將獲得預付款、里程碑付款和版税。該合作旨在改善多種癌症的治療選擇，包括頭頸癌。兩家公司對其對患者和醫療服務提供者的潛在益處表示樂觀</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/PT-2-18-11-2025-shutterstock_2309849697-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/PT-2-18-11-2025-shutterstock_2309849697-430x241.jpg"/></p>
<p>Halozyme owns proprietary enzyme rHuPH20, underpinning Enhanze, a solution for rapid subcutaneous drug delivery. Credit: SaiArLawKa2/Shutterstock.com.</p>
<div class="lb-trans"><p>Halozyme 擁有專有酶 rHuPH20，支撐 Enhanze，這是一種快速皮下藥物遞送的解決方案。圖片來源：SaiArLawKa2/Shutterstock.com。</p>
</div><p>Merus and Halozyme have signed a worldwide non-exclusive partnership and licence agreement for subcutaneous formulation of petosemtamab.</p>
<div class="lb-trans"><p>Merus 和 Halozyme 簽署了一項全球非獨佔合作和許可協議，用於 petosemtamab 的皮下製劑。</p>
</div><p>The agreement involves the development and commercialisation of the administration of petosemtamab, an epidermal growth factor receptor (EGFR) times leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) bispecific antibody, using Enhanze drug delivery technology.</p>
<div class="lb-trans"><p>該協議涉及使用 Enhanze 藥物遞送技術開發和商業化 petosemtamab 的給藥，該藥物是一種表皮生長因子受體 (EGFR) 與富含亮氨酸重複的 G 蛋白偶聯受體 5 (LGR5) 的雙特異性抗體。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - Lemzoparlimab in Marginal Zone B-cell Lymphoma</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - Lemzoparlimab 在邊緣區 B 細胞淋巴瘤中的應用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - Lemzoparlimab in Peritoneal Cancer</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - Lemzoparlimab 在腹膜癌中的應用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>Merus licensed Halozyme’s Enhanze technology to accelerate advancement for the subcutaneous administration.</p>
<div class="lb-trans"><p>Merus 授權 Halozyme 的 Enhanze 技術，以加速皮下給藥的進展。</p>
</div><p>Halozyme will receive an upfront fee, additional payments linked to commercial milestones and sales success from Meru, and low to mid single-digit royalties on net sales of petosemtamab formulated with the technology during the royalty period.</p>
<div class="lb-trans"><p>Halozyme 將獲得預付款、與商業里程碑和銷售成功相關的額外付款，以及在特許權使用費期間對使用該技術製備的 petosemtamab 的淨銷售額的低至中單數字的特許權使用費。</p>
</div><p>Merus chief operating officer and general counsel Peter Silverman stated: “Petosemtamab continues to show encouraging results in the clinical studies across numerous solid tumour cancers and has the potential to become a first and best in class treatment in head and neck cancer and beyond.</p>
<div class="lb-trans"><p>Merus 首席運營官兼總法律顧問 Peter Silverman 表示：“Petosemtamab 在眾多實體腫瘤癌症的臨牀研究中繼續顯示出令人鼓舞的結果，並有潛力成為頭頸癌及其他領域的首個和最佳治療方案。</p>
</div><p>“We are proud to collaborate with Halozyme and look forward to working closely with their team on a subcutaneous administration.”</p>
<div class="lb-trans"><p>“我們很自豪能與 Halozyme 合作，並期待與他們的團隊密切合作進行皮下給藥。”</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預測？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報</p>
</div><p>Halozyme president and CEO Dr Helen Torley stated: “We are excited to collaborate with Merus to advance treatment options for patients with r/m HNSCC and other potential indications.</p>
<div class="lb-trans"><p>Halozyme 總裁兼首席執行官 Dr Helen Torley 表示：“我們很高興能與 Merus 合作，推進 r/m HNSCC 患者及其他潛在適應症的治療選擇。</p>
</div><p>“This collaboration represents a new opportunity for our Enhanze technology to improve treatment efficiency and enhance the patient treatment experience. Together, we aim to accelerate innovation for patients and healthcare providers.”</p>
<div class="lb-trans"><p>“這次合作代表了我們 Enhanze 技術改善治療效率和提升患者治療體驗的新機會。我們共同的目標是加速患者和醫療提供者的創新。”</p>
</div><p>Halozyme owns the enzyme rHuPH20 which underpins Enhanze, a solution enabling rapid subcutaneous drug delivery to lessen the treatment burden on patients.</p>
<div class="lb-trans"><p>Halozyme 擁有酶 rHuPH20，支撐 Enhanze，這是一種快速皮下藥物遞送的解決方案，以減輕患者的治療負擔。</p>
</div><p>The Enhanze technology has been licensed by companies including Takeda, Roche, Janssen, Pfizer and AbbVie.</p>
<div class="lb-trans"><p>Enhanze 技術已被包括 Takeda、Roche、Janssen、Pfizer 和 AbbVie 在內的公司許可。</p>
</div><p>In September 2025, Genmab signed an agreement to buy all shares of Merus at $97 per share, in an all-cash transaction valued at $8bn, boosting its oncology pipeline.</p>
<div class="lb-trans"><p>在 2025 年 9 月，Genmab 簽署了一項協議 以每股 97 美元的價格收購 Merus 的所有股份，此次全現金交易的估值為 80 億美元，增強了其腫瘤學管線。</p>
</div><h2>Pharmaceutical Technology Excellence Awards - The Benefits of Entering</h2>
<div class="lb-trans"><h2>製藥技術卓越獎 - 參賽的好處</h2>
</div><p>Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!</p>
<div class="lb-trans"><p>獲得你應得的認可！製藥技術卓越獎 慶祝創新、領導力和影響力。通過參賽，你展示了你的成就，提升了你的行業形象，並將自己定位於推動製藥進步的頂尖領導者之中。不要錯過脱穎而出的機會——今天就提交你的參賽作品！</p>
</div><p>Nominate Now</p>
<div class="lb-trans"><p>立即提名</p>
</div>

Merus BV 和奧洛茲美醫療在皮下注射 petosemtamab 方面展開合作